<p>IL-6 (panel A) and CCL5 (panel B): production by LNCaP cells left untreated (open bars), stimulated by cross-linking via anti PSMA mAb (filled bars) or anti-VCAM-1 mAb (dashed bars) in the presence or in the absence of single or combined inhibitors (SB and PD) at the indicated doses (SB50 = 50 µg/ml, SB25 = 25 µg/ml; PD50 = 50 µg/ml, PD25 = 25 µg/ml; SB/PD25 = combinations of SB+PD at 25 µg/ml each). Control and treated cell cultures were washed, cultured for further 24 h before collecting cells and cell-free supernatants. IL-6 and CCL5 accumulation in each supernatant was measured by ELISA and expressed as pg/mg of cell lysates/24 h. Inhibitors were added to the cells 6 h prior to stimulation and maintained throughout the duration of th...
<p>Human PBMCs were pre-exposed to IL-6/sIL-6R for 1 hour. Cells were then stimulated with IL-1β (1 ...
<p>A. SiCo and uPARsi human VSMC were treated with 1.2(A) and serine phosphorylation (B) was assesse...
<p>Human PBMCs were exposed to IL-6 (10 ng/ml) in combination with sIL-6R (125 ng/ml) (IL-6/sIL-6R) ...
The interleukin-6 (IL-6) and the chemokine CCL5 are implicated in the development and progression of...
<p>A) LNCaP proliferation induced by treatment with CCL5 and/or IL-6. <sup>3</sup>H-TdR uptake of ce...
<p>(A) Representative western blot of STAT-3, pSTAT-3 and Bcl-2 of B-1 cells cultivated alone (line ...
a)<p>The 7E11c mAb recognizes an intracellular PSMA epitope and is therefore used as a further contr...
<p>Wildtype (WT) BMDMs (1 x10<sup>6</sup> cells) pre-treated for 30 minutes with pharmacological inh...
<p>(A) LNCaP cells were activated by antibody-induced cross-linking of PSMA at 37°C or 4°C. Subseque...
<p>Human PBMCs were pre-exposed to IL-6/sIL-6R for 1 hour. Cells were then stimulated with poly(I-C)...
<p>In short, purified PBMCs were incubated for 30-6 (1, 10 or 100 ng/mL) or the supernatant from cel...
<p>PBMCs and PBLs were prepared as described in the Materials and Methods, stimulated for 1, 3 or 6-...
<p>(A, B) Cells were treated with UDP alone or co-incubated with p38 MAPK inhibitor, SB 203580 (50 µ...
The interleukin-6 (IL-6) and the chemokine CCL5 are implicated in the development and progression of...
<p>(A) WT PMφ were stimulated with LPS (100 ng/mL) for 24 h in the absence (none) or presence (low, ...
<p>Human PBMCs were pre-exposed to IL-6/sIL-6R for 1 hour. Cells were then stimulated with IL-1β (1 ...
<p>A. SiCo and uPARsi human VSMC were treated with 1.2(A) and serine phosphorylation (B) was assesse...
<p>Human PBMCs were exposed to IL-6 (10 ng/ml) in combination with sIL-6R (125 ng/ml) (IL-6/sIL-6R) ...
The interleukin-6 (IL-6) and the chemokine CCL5 are implicated in the development and progression of...
<p>A) LNCaP proliferation induced by treatment with CCL5 and/or IL-6. <sup>3</sup>H-TdR uptake of ce...
<p>(A) Representative western blot of STAT-3, pSTAT-3 and Bcl-2 of B-1 cells cultivated alone (line ...
a)<p>The 7E11c mAb recognizes an intracellular PSMA epitope and is therefore used as a further contr...
<p>Wildtype (WT) BMDMs (1 x10<sup>6</sup> cells) pre-treated for 30 minutes with pharmacological inh...
<p>(A) LNCaP cells were activated by antibody-induced cross-linking of PSMA at 37°C or 4°C. Subseque...
<p>Human PBMCs were pre-exposed to IL-6/sIL-6R for 1 hour. Cells were then stimulated with poly(I-C)...
<p>In short, purified PBMCs were incubated for 30-6 (1, 10 or 100 ng/mL) or the supernatant from cel...
<p>PBMCs and PBLs were prepared as described in the Materials and Methods, stimulated for 1, 3 or 6-...
<p>(A, B) Cells were treated with UDP alone or co-incubated with p38 MAPK inhibitor, SB 203580 (50 µ...
The interleukin-6 (IL-6) and the chemokine CCL5 are implicated in the development and progression of...
<p>(A) WT PMφ were stimulated with LPS (100 ng/mL) for 24 h in the absence (none) or presence (low, ...
<p>Human PBMCs were pre-exposed to IL-6/sIL-6R for 1 hour. Cells were then stimulated with IL-1β (1 ...
<p>A. SiCo and uPARsi human VSMC were treated with 1.2(A) and serine phosphorylation (B) was assesse...
<p>Human PBMCs were exposed to IL-6 (10 ng/ml) in combination with sIL-6R (125 ng/ml) (IL-6/sIL-6R) ...